Search Results 251-260 of 18471 for Relapse

  1. A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW) - Mayo Clinic

    ... relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD). Participation eligibility. Participant ...

  2. Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    This phase II trial studies how well lenalidomide and dexamethasone work in treating patients with relapsed or refractory multiple myeloma. Biological ...

  3. Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas - Mayo Clinic

    Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas · Overview · Participation eligibility.

  4. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...

  5. Addiction Services - Overview - Mayo Clinic

    The goal of treatment is to prevent relapse and improve quality of life by providing the most up-to-date care in a highly professional setting. Mayo Clinic ...

  6. Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma - Mayo Clinic

    Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin ...

  7. Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients with Relapsed or Refractory ALL - Mayo Clinic

    This study seeks adult subjects with Relapsed/Refractory (R/R) B-precursor ALL. This is a phase 3 randomized, open label study designed to evaluate the efficacy ...

  8. Study Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Using Nivolumab with or without Varlilumab - Mayo Clinic

    Monoclonal antibodies, such as varlilumab and nivolumab, may work by stimulating the immune system to attack cancer tumor cells. Participation eligibility.

  9. S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma - Mayo Clinic

    S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma · Overview · Participation eligibility · Participating Mayo Clinic ...

  10. A Study of Using Bortezomib and Combination Chemotherapy in Treating Children with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma - Mayo Clinic

    A Study of Using Bortezomib and Combination Chemotherapy in Treating Children with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. Print ...